Recent Advances in Managing Spinal Intervertebral Discs Degeneration

Int J Mol Sci. 2022 Jun 9;23(12):6460. doi: 10.3390/ijms23126460.

Abstract

Low back pain (LBP) represents a frequent and debilitating condition affecting a large part of the global population and posing a worldwide health and economic burden. The major cause of LBP is intervertebral disc degeneration (IDD), a complex disease that can further aggravate and give rise to severe spine problems. As most of the current treatments for IDD either only alleviate the associated symptoms or expose patients to the risk of intraoperative and postoperative complications, there is a pressing need to develop better therapeutic strategies. In this respect, the present paper first describes the pathogenesis and etiology of IDD to set the framework for what has to be combated to restore the normal state of intervertebral discs (IVDs), then further elaborates on the recent advances in managing IDD. Specifically, there are reviewed bioactive compounds and growth factors that have shown promising potential against underlying factors of IDD, cell-based therapies for IVD regeneration, biomimetic artificial IVDs, and several other emerging IDD therapeutic options (e.g., exosomes, RNA approaches, and artificial intelligence).

Keywords: artificial intervertebral discs; cell-based therapies; intervertebral disc degeneration; intervertebral disc repair; regeneration strategies.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Intervertebral Disc Degeneration* / etiology
  • Intervertebral Disc Degeneration* / pathology
  • Intervertebral Disc Degeneration* / therapy
  • Intervertebral Disc* / pathology
  • Low Back Pain* / etiology
  • Low Back Pain* / therapy

Substances

  • Intercellular Signaling Peptides and Proteins

Grants and funding

This research received no external funding.